The effect of hyperglycinemic treatment in captive-bred Vervet monkeys (Chlorocebus aethiops)
- 34 Downloads
Nonketotic hyperglycinemia (NKH) is a neuro-metabolic disorder caused by a deficiency in the glycine cleavage system (GCS) and glycine transporter 1 (GlyT1). A case of atypical late onset of NKH has been reported in a colony of captive-bred Vervet monkeys. The purpose of this study was to evaluate the effect of sodium benzoate and dextromethorphan in reducing glycine levels in hyperglycinemic monkeys. Twelve captive-bred Vervet monkeys were assigned into three groups consisting of four animals (control, valproate induced and cataract with spontaneous hyperglycinemia). Valproate was used to elevate glycine levels and the induced group was then treated with sodium benzoate and dextromethorphan together with group three to normalise glycine levels in cerebrospinal fluid (CSF) and plasma. Valproate induction elicited changes in phosphate, alkaline phosphatase and platelet count, however, no significant changes in the glycine levels were observed, and this might be due to the individual variability within the group. The treatment intervention was only obtained in the spontaneous group whereby the glycine levels were normalised in CSF and plasma. Therefore, it can be concluded that sodium benzoate and dextromethorphan treatment was effective and beneficial to the hyperglycinemic group.
KeywordsDextromethorphan Glycine Sodium benzoate Spontaneous hyperglycinemia Valproate and Vervet monkey
The authors express their gratitude to Joritha van Heerden, Timothy Collop and Abraham Davids for their excellent expertise in handling Vervet monkeys. The South African Medical Research Council/ Primate Unit and Delft Animal Centre for financial support.
The authors did not receive any research grant for this study, however, financial support was provided by the Primate Unit and Delft Animal Centre (PUDAC) of the South African Medical Research Council.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This study was approved by the SAMRC Ethics Committee for Research on Animals (ECRA) (Ref.08/13). All procedure performed in study involving animals were in accordance with the ethical standards of the South African National Standard for the Care and Use of Animals for Scientific Purposes (South African Bureau of Standards, SANS 10386, 2008).
- Aghebati T, Foroughipour M, Azarpazhooh MR, Mokhber N, Khayat MH, Vahdati N, Mohammadpour AH (2012) Relationship between patient demographic characteristics, Valproic acid dosage and clearance in adult Iranian patients. Iran J Basic Med Sci 15:702Google Scholar
- Gregus Z, Fekete T, Halászi É, Gyurasics Á, Klaassen CD (1998) Effects of fibrates on the glycine conjugation of benzoic acid in rats. Drug Metab Dispos 26:1082–1088Google Scholar
- Hejtmancik J. F. Congenital cataracts and their molecular genetics. Semin Cell Dev Biol, 2008. Elsevier, 134–149Google Scholar
- Hussain S, Mordekar S, Prasad M (2013) The calm before the storm?: late onset Glycine encephalopathy masquerading as gastro-oesophageal reflux. J Neurodev Disord 2013Google Scholar
- Karaoglu A, Vurucu S, Okutan V, Kurekci AE, Caycý T, Atay A, Akin R, Gokcay E (2009) Valporic acid: is it safe to use in epileptic pediatric patient? Pak J Med Sci July–September 25:539–544Google Scholar
- Kojima-Ishii K, Kure S, Ichinohe A, Shinka T, Narisawa A, Komatsuzaki S, Kanno J, Kamada F, Aoki Y, Yokoyama H (2008) Model mice for mild-form glycine encephalopathy: behavioral and biochemical characterizations and efficacy of antagonists for the glycine binding site of N-methyl D-aspartate receptor. Pediatr Res 64:228–233CrossRefGoogle Scholar
- Star K., Edwards I. R.. Choonara I. (2014). Valproic acid and fatalities in children: a review of individual case safety reports in VigiBaseGoogle Scholar